

3. (Amended) A delayed release coated core according to claim 2 wherein the ammonio methacrylate copolymers are of type A or B.

4. (Amended) A delayed release coated core according to Claim 3 wherein the cationic surfactants are chosen from trimethyl-dimyristoyl-ammonium propionate, dimethyl-dioctadecyl-ammonium bromide, trimethyl-cetyl-ammonium bromide, dimethyl-didodecyl--ammonium bromide, benzalkonium chloride, cetylpyridinium chloride and cetrimide and the zwitterionic surfactants are chosen from N-allylbetaines, C-alkylbetaines, N-alkylamidobetaines, N-alkylglycines, phosphatidylcholines and lecithins.

6. (Amended) A delayed release coated core according to claim 4 wherein the zwitterionic surfactant is cocamidopropylbetaine.

7. (Amended) A delayed release coated core according to Claim 3 wherein the active substance is chosen from diltazem, theophylline, felodipine, verapamil, clonidine, acebutolol, alprenolol, betaxolol, metoprolol, nadolol, propranolol, timolol, captopril, enalapril, fosinopril, tiapamil, gallopamil, amlodipine, nitrendipine, nisoldipine, nicardipine, felodipine, molsidamine, indomethacin, sulindac, indoprofen, ketoprofen, flurbiprofen, fenbufen, fluprofen, diclofenac, tiaprofenic acid, naproxen, mizolastin, terbutaline, salbutamol, betamethasone, prednisone, methylprednisone, dexamethasone, prednisolone, sumatriptan, naratriptan, cimetidine, ranitidine, famotidine, nizatidine, omeprozole, morphine, fenoprofen, ibuprofen, ketoprofen, alclofenac, mefenamic, alfuzosin, prazosin, tamulosin, levodopa and methyl dopa, their salts and pharmacologically active esters.

8. (Amended) A delayed release coated core according to Claim 3 in the form of a particle, pellet, bead, granule or spheroid, of a diameter comprised between 0.3 and 3 mm.

9. (Amended) A delayed release coated core according to Claim 3 in the form of a tablet or a minitabiet.

11. (Amended) A delayed release coated core according to Claim 3 wherein the core is separated from the polymer coating by a layer of water soluble polymer.

12. (Amended) A delayed release coated core according to claim 11 wherein the soluble polymer is chosen from hydroxypropylmethylcellulose, hydroxyethylcellulose and polyvinylpyrrolidone.

13. (Amended) A pharmaceutical dosage form comprising a delayed release coated core according to Claim 3.

14. (Amended) A pharmaceutical dosage form according to claim 13 in the form of a tablet, a multilayer tablet, a multicoated tablet or a capsule.

15. (Amended) A pharmaceutical dosage form according to claim 13 wherein coated cores of differing delayed release times are combined together to give a "stepped" release profile.

16. (Amended) A pharmaceutical dosage form according to claim 13 wherein the delayed release coated core is combined with another galenic entity, the release of said entity being immediate or sustained.

17. (Amended) A pharmaceutical dosage form according to claim 16 wherein the other galenic entity contains an active substance different from the active substance in the delayed release coated core.

18. (Amended) A pharmaceutical dosage form according to claim 16 wherein a first release pulse occurs immediately and a second release pulse is delayed for a fixed time.

19. (Amended) A capsule according to claim 16 comprising a delayed release coated core in the form of a particle, pellet, bead granule or spheroid having a diameter of 0.3 to 3 mm or in the form of a minitab, and an immediate and/or sustained release entity chosen from

(i) immediate release particles or minitab, and an immediate release granulate or powder, and

(ii) controlled release particles or minitab.

20. (Amended) A tablet according to claim 16 wherein the delayed release coated core in the form of a particle, pellet, bead granule or spheroid having a diameter of 0.3 to 3 mm is imbedded in a rapidly disintegrating matrix.

1124 / 464, 465 472, 480, 451

21. (Amended) A capsule according to claim 16 comprising one or more immediate release tablets and one or more delayed release coated cores in the form of tablets.

AB 22. (Amended) A multicoated tablet according to claim 16 coated with an immediate release soluble or disintegrable coating.

Please cancel claims 5 and 10

Please add the following new claims:

--23. (New) A tablet according to claim 20 wherein the matrix is free of active substance. 4-28/402

24. (New) A tablet according to claim 20 wherein the matrix also contains active substance.

25. (New) A tablet according to claim 20 wherein sustained release particles are mixed with the delayed release coated particles.

26 (New) A tablet according to claim 20 wherein immediate release particles are mixed with the delayed release coated particles.

27. (New) A tablet according to claim 20 wherein the delayed release coated particles are further coated with a layer containing the active substance.

28. (New) A tablet according to claim 20 comprising one or more layers containing the delayed release particles in the rapidly disintegrating matrix and one or more layers containing the active substance in an immediate release matrix.

29. (New) A delayed release coated core according to claim 3, said core further containing a pharmaceutically acceptable organic acid.

30. (New) ) A delayed release coated core according to claim 4, said core further containing an acid chosen from maleic, tartaric, malic, fumaric, lactic, citric, adipic and succinic acid or a salt thereof.

31. (New) A delayed release coated core according to claim 30 wherein the acid is chosen from tartaric, fumaric, citric and succinic acid or salt thereof.

32. (New) A delayed release coated core according to claim 31 wherein the acid is succinic or tartaric acid and the surfactant is cetylpyridinium chloride or cocamidopropylbetaine.

33. (New) A delayed release coated core according to claim 32 wherein the active substance is alfuzosin or an acid-addition salt thereof.

34. (New) A delayed release coated core according to claim 32 wherein the active substance is a hypnotic---.